FDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

Eli Lilly and Co said on Friday the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

Source: Reuters: Health - February 22, 2020 Category: Consumer Health News Tags: healthNews Source Type: news